Disappearance of cryoproteins in the sera of a patient with SLE after treatment with blisibimod, a novel subcutaneous anti-B cell therapy.
Department of Rheumatology, Instituto Israelita de Ensino e Pesquisa Albert Einstein, Albert Einstein Avenue 627, Sao Paulo 05651-901, Brazil. morton@osite.com.br.
Andrea Pimentel Fonseca
AP
Golmia
Renee
R
Martin
Colin
C
Hislop
Morton
M
Scheinberg
D053264:B-Cell Activating Factor / Q000187:drug effects; D001402:B-Lymphocytes / Q000187:drug effects / Q000473:pathology*; D049109:Cell Proliferation / Q000187:drug effects; D003450:Cryoglobulins / Q000378:metabolism*; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D008180:Lupus Erythematosus, Systemic / Q000097:blood* / Q000188:drug therapy*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome
C573858:AMG623 peptibody; D053264:B-Cell Activating Factor; D003450:Cryoglobulins; D011993:Recombinant Fusion Proteins; C505719:TNFSF13B protein, human